BioCentury | Feb 18, 2021
Finance

With $300M fund, Adjuvant picks its spots among start-ups addressing global public health needs

...ApS, a Danish start-up developing a Group B Streptococcus vaccine; publicly traded women’s health company Evofem Biosciences Inc....
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc. $60.0 Genomics plc $58.1 Theravance Biopharma Inc. (NASDAQ:TBPH) $55.0 Evofem Biosciences Inc....
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc. $60.0 Genomics plc $58.1 Theravance Biopharma Inc. (NASDAQ:TBPH) $55.0 Evofem Biosciences Inc....
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...GIST) Phase III data Mid-2019 Epizyme Inc. (NASDAQ:EPZM) Tazemetostat Treat epithelioid sarcoma Submit NDA 2Q19 Evofem Biosciences Inc....
BioCentury | Jan 11, 2019
Clinical News

Evofem to resubmit NDA for hormone-free contraceptive

...cohorts in the Phase III AMP001 trial to prevent pregnancy, despite meeting its primary endpoint. Evofem...
...18-35 and evaluated the cumulative pregnancy rate over seven 21-35 day cycles of Amphora use. Evofem Biosciences Inc....
...pregnancy rate over seven 21-35 day cycles Status: Phase III data Milestone: Resubmit NDA (2Q19) Sandi Wong Amphora Evofem Biosciences Inc. Contraception...
BioCentury | Sep 1, 2016
Company News

Management tracks

...and transition to a part-time role as executive medical director. Lynch also is chairman of Evofem...
BioCentury | Aug 22, 2016
Clinical News

Amphora: Phase I started

...gel vs. a hydroxyethylcellulose placebo gel or no treatment in about 100 healthy female volunteers. Evofem...
Items per page:
1 - 7 of 7
BioCentury | Feb 18, 2021
Finance

With $300M fund, Adjuvant picks its spots among start-ups addressing global public health needs

...ApS, a Danish start-up developing a Group B Streptococcus vaccine; publicly traded women’s health company Evofem Biosciences Inc....
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc. $60.0 Genomics plc $58.1 Theravance Biopharma Inc. (NASDAQ:TBPH) $55.0 Evofem Biosciences Inc....
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc. $60.0 Genomics plc $58.1 Theravance Biopharma Inc. (NASDAQ:TBPH) $55.0 Evofem Biosciences Inc....
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...GIST) Phase III data Mid-2019 Epizyme Inc. (NASDAQ:EPZM) Tazemetostat Treat epithelioid sarcoma Submit NDA 2Q19 Evofem Biosciences Inc....
BioCentury | Jan 11, 2019
Clinical News

Evofem to resubmit NDA for hormone-free contraceptive

...cohorts in the Phase III AMP001 trial to prevent pregnancy, despite meeting its primary endpoint. Evofem...
...18-35 and evaluated the cumulative pregnancy rate over seven 21-35 day cycles of Amphora use. Evofem Biosciences Inc....
...pregnancy rate over seven 21-35 day cycles Status: Phase III data Milestone: Resubmit NDA (2Q19) Sandi Wong Amphora Evofem Biosciences Inc. Contraception...
BioCentury | Sep 1, 2016
Company News

Management tracks

...and transition to a part-time role as executive medical director. Lynch also is chairman of Evofem...
BioCentury | Aug 22, 2016
Clinical News

Amphora: Phase I started

...gel vs. a hydroxyethylcellulose placebo gel or no treatment in about 100 healthy female volunteers. Evofem...
Items per page:
1 - 7 of 7